Evaluation of the Signal to Noise Ratio at Various Retinal Layers

June 6, 2022 updated by: Topcon Medical Systems, Inc.

Evaluation of the Signal to Noise Ratio at Various Retinal Layers in Spectral Domain Optical Coherence Tomography (SD OCT) Compared to Swept Source Optical Coherence Tomography (SS OCT)

Compare the signal to noise ratio of each device at various retinal layers.

Study Overview

Status

Completed

Conditions

Detailed Description

Compare the signal to noise ratio of each device (SD OCT and SS OCT) at various retinal layers from the same group of subjects

Study Type

Observational

Enrollment (Actual)

15

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Jersey
      • Oakland, New Jersey, United States, 07436
        • Topcon Medical Systems Inc.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

30 subjects willing to participate in this study.

Description

Inclusion Criteria:

  1. Male or female patients > 18 years old who have full legal capacity to volunteer on the date the informed consent is signed.
  2. Subjects who can follow the instructions by the clinical staff at the clinical site, and can attend examinations on the scheduled examination date.
  3. Subjects who agree to participate in the study.

Exclusion Criteria:

  1. History of cataract or ocular surgical procedures that render the cornea opaque or otherwise impact its ability to be imaged using the investigational device.
  2. Fixation problems which may prevent obtaining good quality images in either eye.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Normal Eyes
Subjects with no known ocular diseases will be imaged on the 3D OCT-1 Maestro and DRI OCT Triton
Image acquisition of the posterior surface of the eye
Image acquisition of the posterior surface of the eye

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Signal to noise ratio between SD OCT and SS OCT
Time Frame: 5 minutes
5 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2016

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

January 1, 2017

Study Registration Dates

First Submitted

November 29, 2016

First Submitted That Met QC Criteria

November 30, 2016

First Posted (Estimate)

December 5, 2016

Study Record Updates

Last Update Posted (Actual)

June 8, 2022

Last Update Submitted That Met QC Criteria

June 6, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • Topcon-601-2016

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Eyes

Clinical Trials on 3D OCT-1 Maestro

Subscribe